Eli Lilly to acquire CoLucid for $960 million
INDIANAPOLIS — Eli Lilly and Co. plans to buy CoLucid Pharmaceuticals Inc., maker of a promising migraine medication, for about $960 million in cash. Cambridge, Mass.-based CoLucid is currently in development with lasmiditan tablets, indicated for acute treatment of migraine, and has completed the first of two Phase 3 trials. A data read-out for the
